Sentiment-Signal
8,1
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Unternehmen & Branche
| Name | ARS Pharmaceuticals, Inc. |
|---|---|
| Ticker | SPRY |
| CIK | 0001671858 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 788,4 Mio. USD |
| Beta | 0,93 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 84,278,000 | -171,298,000 | -1.74 | 327,652,000 | 114,258,000 |
| 2025-09-30 | 10-Q | 32,501,000 | -51,151,000 | -0.52 | 372,803,000 | 147,655,000 |
| 2025-06-30 | 10-Q | 15,717,000 | -44,883,000 | -0.46 | 313,472,000 | 192,321,000 |
| 2025-03-31 | 10-Q | 7,973,000 | -33,940,000 | -0.35 | 327,318,000 | 228,974,000 |
| 2024-12-31 | 10-K | 89,149,000 | 7,998,000 | 0.08 | 351,153,000 | 256,798,000 |
| 2024-09-30 | 10-Q | 2,068,000 | -19,128,000 | -0.20 | 217,601,000 | 200,978,000 |
| 2024-06-30 | 10-Q | 500,000 | -12,516,000 | -0.13 | 221,966,000 | 215,241,000 |
| 2024-03-31 | 10-Q | 0 | -10,292,000 | -0.11 | 227,583,000 | 223,868,000 |
| 2023-12-31 | 10-K | 30,000 | -54,365,000 | -0.57 | 233,188,000 | 230,760,000 |
| 2023-09-30 | 10-Q | 0 | -14,866,000 | -0.16 | 248,556,000 | 237,284,000 |
| 2023-06-30 | 10-Q | 10,000 | -17,370,000 | -0.18 | 258,752,000 | 248,552,000 |
| 2023-03-31 | 10-Q | 20,000 | -14,961,000 | -0.16 | 271,192,000 | 261,155,000 |
| 2022-12-31 | 10-K | 1,316,000 | -34,682,000 | -0.87 | 281,435,000 | 272,886,000 |
| 2022-09-30 | 10-Q | 189,000 | -6,583,000 | -0.21 | 271,064,000 | -50,155,000 |
| 2022-06-30 | 10-Q | 464,000 | -6,420,000 | -0.21 | 293,999,000 | -44,032,000 |
| 2022-03-31 | 10-Q | 663,000 | -7,250,000 | -0.24 | 312,469,000 | -38,255,000 |
| 2021-12-31 | 10-K | 5,506,000 | -20,243,000 | -0.70 | 61,446,000 | -31,269,000 |
| 2021-09-30 | 10-Q | -22,655,000 | -0.65 | 352,561,000 | 332,134,000 | |
| 2021-06-30 | 10-Q | -24,496,000 | 366,976,000 | 349,650,000 | ||
| 2021-03-31 | 10-Q | -18,867,000 | 382,199,000 | 368,549,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-11-13 | Dorsey Brian | Officer, Chief Operating Officer | Open Market Sale | -21,828 | 8.71 | -190,049.85 | -12,5% | |
| 2025-11-12 | Chakma Justin | Officer, Chief Business Officer | Open Market Sale | -136,380 | 8.86 | -1,208,790.49 | -79,4% | |
| 2025-11-12 | Chakma Justin | Officer, Chief Business Officer | Open Market Sale | -30,000 | 8.91 | -267,357.00 | -17,6% | |
| 2025-08-21 | Scott Kathleen D. | Officer, Chief Financial Officer | Open Market Sale | -12,500 | 15.00 | -187,500.00 | -12,3% | |
| 2025-08-21 | Lowenthal Richard E | Director, Officer, 10% Owner, PRESIDENT AND CEO | Open Market Sale | -50,000 | 14.49 | -724,345.00 | -47,6% | |
| 2025-08-20 | Tanimoto Sarina | Officer, 10% Owner, CHIEF MEDICAL OFFICER | Open Market Sale | -37,656 | 14.09 | -530,625.76 | -34,9% | |
| 2025-08-19 | Tanimoto Sarina | Officer, 10% Owner, CHIEF MEDICAL OFFICER | Open Market Sale | -12,344 | 14.03 | -173,129.54 | -11,4% | |
| 2025-07-01 | Karas Eric | Officer, Chief Commercial Officer | Open Market Sale | -15,000 | 16.99 | -254,860.50 | -16,7% | |
| 2025-06-27 | Flynn James E | 10% Owner | Open Market Sale | -370,075 | 18.46 | -6,831,584.50 | -448,9% | |
| 2025-06-27 | Flynn James E | 10% Owner | Open Market Sale | -370,074 | 18.46 | -6,831,566.04 | -448,9% | |
| 2025-06-18 | Karas Eric | Officer, Chief Commercial Officer | Open Market Sale | -15,000 | 16.00 | -240,000.00 | -15,8% | |
| 2025-05-20 | SAUNDERS BRENT L | Director | Open Market Sale | -120,000 | 14.25 | -1,710,024.00 | -112,4% | |
| 2025-05-20 | Fitzpatrick Alexander A | Officer, Chief Legal Officer | Open Market Sale | -102,969 | 14.10 | -1,451,512.81 | -95,4% | |
| 2025-05-20 | Scott Kathleen D. | Officer, Chief Financial Officer | Open Market Sale | -50,000 | 14.10 | -705,165.00 | -46,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.